We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Events

19 May 2026 - 22 May 2026
17 Jun 2026 - 19 Jun 2026

An Innovative Glove Measures Blood Flow in the Prostate

By HospiMedica staff writers
Posted on 11 Mar 2008
A second generation prototype sensor for measuring blood flow in the prostate gland during the digital rectal examination (DRE) could potentially help direct the treatment of millions of men with indeterminate prostate specific antigen (PSA) results.

The Urodynamix near infrared spectroscopy (NIRS) DRE system is designed to enhance the traditional DRE procedure by capturing data that will improve the clinicians' ability to detect prostate cancer and other diseases of the prostate such as benign prostatic hyperplasia (BPH). More...
The system consists of a miniaturized single-use disposable sensor and pressure transducer with a console containing proprietary NIRS hardware and software. The sensor is designed to be embedded within an exam glove as a self contained, single use disposable test kit that allows the clinician to measure blood flow as he or she examines the prostate. The procedure is otherwise identical to a conventional DRE. The Urodynamix NIRS DRE system is under development by Urodynamix (Vancouver Island, Canada).

"The technology could provide primary care physicians with the ability to monitor changes in prostate cancer disease progression and assess prostate vascularity in BPH and prostatitis,” said by Dr. Zeid Mohamedali, M.D., Ph.D., principal investigator of the prototype and a member of the Urodynamix board of directors. "Since NIRS DRE technology can be integrated into the existing office DRE procedure, it could also help reduce the number of unnecessary prostate biopsies performed every year.”

The prostate specific antigen (PSA) test and the digital rectal exam (DRE) are currently used to detect and manage prostate cancer, but these techniques suffer from a lack of specificity and selectivity. The traditional DRE has poor accuracy for the detection of prostate cancer, with published sensitivity values ranging between 18% and 68%.


Related Links:
Urodynamix

Gold Member
STI Test
Vivalytic Sexually Transmitted Infection (STI) Array
New
Gold Member
Neonatal Heel Incision Device
Tenderfoot
New
Rapid Sepsis Test
SeptiCyte RAPID
New
Wound Irrigation Solution
Prontosan®
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Copyright © 2000-2026 Globetech Media. All rights reserved.